Antibiotics

IMI/REL was effective against isolates from the United States and Europe.

Pooled analyses of 2 phase 3 trials have conclusively established the safety and effectiveness of iclaprim compared to vancomycin in the treatment of acute bacterial skin and skin structure infections (ABSSSI).

The pooled results have hammered home the promise of eravacycline for the treatment of patients with cIAIs who are colonized by drug-resistant bacteria.

An extremely virulent (hypermucoviscous) strain of Klebsiella pneumoniae that is resistant to carbapenem and colistin has been isolated for the first time from a patient in the United States.

Sixty-nine out of the 70 colistin-resistant isolates had either mcr-1 and/or mcr-3 genes.

Chelsea Drennan, PharmD(c) explains why hospital length-of-stay might be shorter in patients who are on a fluoroquinolone versus a beta-lactam.

Empiric use of fluoroquinolones looks to be an alternate option for the treatment of gram-negative bloodstream infections when risk factors for antimicrobial resistance are not present.

A lack of coordination among regulating bodies, pharma manufacturers, standard development organizations, and laboratory testing device companies has muddied efforts to stop antibiotic resistance; the 21st Century Cures Act aims to fix that.

Increased stewardship may reduce administration of drugs to low birth-weight babies designed to prevent early-onset sepsis.

Stay up-to-date on the latest infectious disease news by checking out our top 5 articles of the week.

Bruce A. Mueller, PharmD, explains the risk factors for augmented renal clearance.